Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-patient modular study of OMO-1 alone and with EGFR-TKIs in advanced solid tumors
NL-OMON48960Phase 1Active, not recruiting
- Sponsor
- OCTIMET Oncology
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-38877618 in Non-hematologic malignancy and cancer (4 arms), sponsored by OCTIMET Oncology. Primary endpoints: Safety and tolerability, Objective response rate and 9 more. Started Nov 2017; status: active, not recruiting.
02
Drugs
JNJ-38877618
03
Conditions
Non-hematologic malignancycancer
Beyond the preview
Go deeper on NL-OMON48960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48960.